M&As this week: Allergen, Primex Pharmaceuticals, Cheisi Farmaceutici
Allergen has acquired Chase Pharmaceuticals Corporation from New Rhein Healthcare Investors for a purchase consideration of $125m.
Allergen has acquired Chase Pharmaceuticals Corporation from New Rhein Healthcare Investors for a purchase consideration of $125m.
Pursuant to the agreement, Chase Pharma will be merged with a subsidiary of Allergan, and Allergan will be responsible to pay additional potential regulatory and sales milestone-based payments to Chase Pharma.
The acquisition will allow the acquirer to further expand its CNS research and development (R&D) pipeline.
"The acquisition will allow the acquirer to further expand its CNS research and development (R&D) pipeline."
Primex Pharmaceuticals has acquired Giovanni Ogna& Figli with the aim of expanding its product portfolio of dental surgery products.
Pursuant to the agreement, Primex will merge all the former OGNA companies into the original company, Giovanni Ogna et Figli.
Chiesi Farmaceutici plans to acquire Atopix Therapeutics by purchasing all its outstanding shares for a purchase consideration of $79.4m.
The acquisition will enable Chiesi Framaceutici to expand its product portfolio for respiratory and eosinophilic airways diseases.